Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors, Cancer, Advanced Solid Malignancies

In brief

This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.

Key facts

Study ID

NCT00473616

Run by

AstraZeneca

People needed

60

Starts

2007-05-01

Expected to finish

2011-01-01

Last updated by the study team

2011-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors for which standard treatment doesn't exist or is no longer effective.
• Must be suitable for treatment with irinotecan
• Relatively good overall health other than your cancer

You may not qualify if…

• Poor bone marrow function (not producing enough blood cells)
• Serious heart conditions
• Poor liver or kidney function
• Any prior anthracycline treatment

Where it is running

• Research Site — Boston, Massachusetts, United States
• Research Site — New York, New York, United States
• Research site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.